EUVIMEDEUVIMED entdecken
Crossref

68Ga-NOTA-FAPI-IF7: A Heterobivalent PET Probe for Dual-Targeted Imaging of Fibroblast Activation Protein and Annexin A1 in Tumor Microenvironment

Wenfang Liao, Xiaotian Guo, Peng Jiang, Kejing Shao, Bao Zhu, Fei Chen iD

Molecular Pharmaceutics · 02.11.2026 · 23 (11) · 5936-5945

DOI: 10.1021/acs.molpharmaceut.6c01158 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmaceutics, online erschienen am 08.10.2026. Verfasst von Wenfang Liao und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, the Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi People's Hospital, Wuxi Medical Center, Nan…. Hauptthemen laut MEDLINE: Tumor Microenvironment, Positron-Emission Tomography, Gallium Radioisotopes, Annexin A1. Die Arbeit nennt 28 Literaturangaben. Gefördert von: Wuxi Health Commission, Wuxi Medical Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Fibroblast activation protein (FAP)-targeted PET tracers enable high-contrast tumor imaging but suffer from rapid clearance and non-specific uptake in inflammatory lesions. The heptapeptide IF7 binds annexin A1 (ANXA1) on tumor vascular endothelium, a target directly accessible from the bloodstream. To overcome these limitations, we developed a heterobivalent PET probe, NOTA-FAPI-IF7, based on a rationally designed dual-targeting strategy that simultaneously engages FAP in cancer-associated fibroblasts and ANXA1 on tumor vasculature. Radiolabeling with 68Ga achieved a radiochemical yield of 92.3 ± 3.6% (decay-corrected, n = 5) with excellent stability (radiochemical purity >97% at all time points). In vitro assays confirmed dual-target binding (IC50 = 27.9 nM, KD = 3.77 nM). Micro-PET imaging demonstrated rapid tumor visualization as early as 10 min post-injection (6.02 ± 0.07% ID/g), with uptake significantly reduced by blocking with excess unlabeled FAPI, IF7, or NOTA-FAPI-IF7. The probe exhibited favorable hydrophilicity (log P = −1.20) and renal clearance with low hepatobiliary uptake. This bispecific strategy, distinct from monospecific and homomultimeric approaches, offers a promising avenue for precision oncologic PET imaging.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tumor MicroenvironmentPositron-Emission TomographyGallium RadioisotopesAnnexin A1Serine EndopeptidasesRadiopharmaceuticalsMembrane ProteinsGelatinasesHumansAnimalsFibroblast Activation Protein AlphaEndopeptidasesMiceCell Line, TumorOligopeptidesFemaleTissue DistributionQuinolines

Stichwörter der Autor:innen

PET imagingannexin A1 (ANXA1)dual-targetingfibroblast activation protein inhibitor (FAPI)radiopharmaceuticals

Substanzen

Fibroblast Activation Protein AlphaGallium RadioisotopesEndopeptidasesAnnexin A1Serine EndopeptidasesRadiopharmaceuticalsMembrane ProteinsGelatinases68Ga-FAPIOligopeptides

Autor:innen und Institutionen

  • Department of Nuclear Medicine, the Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi People's Hospital, Wuxi Medical Center, Nanjing Medical University, Wuxi, Jiangsu214023, P. R. China.

ORCID-Profile: Fei Chen

Förderung

  • Wuxi Health Commission
  • Wuxi Medical Center

Zitieren

APA

Liao, W., Guo, X., Jiang, P., Shao, K., Zhu, B., & Chen, F. (2026). 68Ga-NOTA-FAPI-IF7: A Heterobivalent PET Probe for Dual-Targeted Imaging of Fibroblast Activation Protein and Annexin A1 in Tumor Microenvironment. Molecular Pharmaceutics, 23(11), 5936-5945. https://doi.org/10.1021/acs.molpharmaceut.6c01158

Vancouver

Liao W, Guo X, Jiang P, Shao K, Zhu B, Chen F. 68Ga-NOTA-FAPI-IF7: A Heterobivalent PET Probe for Dual-Targeted Imaging of Fibroblast Activation Protein and Annexin A1 in Tumor Microenvironment. Molecular Pharmaceutics. 2026;23(11):5936-5945. doi:10.1021/acs.molpharmaceut.6c01158

BibTeX
@article{Liao2026,
  author = {Liao, Wenfang and Guo, Xiaotian and Jiang, Peng and Shao, Kejing and Zhu, Bao and Chen, Fei},
  title = {68Ga-NOTA-FAPI-IF7: A Heterobivalent PET Probe for Dual-Targeted Imaging of Fibroblast Activation Protein and Annexin A1 in Tumor Microenvironment},
  journal = {Molecular Pharmaceutics},
  year = {2026},
  volume = {23},
  number = {11},
  pages = {5936--5945},
  doi = {10.1021/acs.molpharmaceut.6c01158}
}
Kostenlos starten →